Researchers from National Health Insurance Service Ilsan Hospital Detail Research in Prostate Cancer (Usefulness of grayscale values of hypoechoic lesions matched with target lesions observed on magnetic resonance imaging for the prediction of …): Oncology – Prostate Cancer

2022 NOV 10 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Daily -- Investigators publish new report on prostate cancer. According to news reporting from the National Health Insurance Service Ilsan Hospital by NewsRx journalists, research stated, “To analyze grayscale values for hypoechoic lesions matched with target lesions evaluated using prebiopsy magnetic resonance imaging (MRI) according to the Prostate Imaging-Reporting and Data System (PI-RADS). We collected data on 420 target lesions in patients who underwent MRI/transrectal ultrasound fusion-targeted biopsies between January 2017 and September 2020.”

Funders for this research include Grant of Patient-centered Clinical Research Coordinating Center Funded By The Ministry of Health & Welfare, Republic of Korea.

Our news journalists obtained a quote from the research from National Health Insurance Service Ilsan Hospital: “Images of hypoechoic lesions that matched the target lesions on MRI were stored in a picture archiving and communication system, and their grayscale values were estimated using the red/green/blue scoring method through an embedded function. We analyzed imaging data using grayscale values. Of the 420 lesions, 261 (62.1%) were prostate cancer lesions. There was no difference in the median grayscale values between benign and prostate cancer lesions. However, grayscale ranges (41.8-98.5 and 42.6-91.8) were significant predictors of prostate cancer and clinically significant prostate cancer (csPC) in multivariable logistic regression analyses. Area under the curve for detecting csPC using grayscale values along with conventional variables (age, prostate-specific antigen levels, prostate volume, previous prostate biopsy results, and PI-RADS scores) was 0.839, which was significantly higher than that for detecting csPC using only conventional variables (0.828; P = 0.036). Subgroup analysis revealed a significant difference for PI-RADS 3 lesions between grayscale values for benign and cancerous lesions (74.5 vs. 58.8, P = 0.008). Grayscale values were the only significant predictive factor (odds ratio = 4.46, P = 0.005) for csPC.”

According to the news reporters, the research concluded: “Distribution of grayscale values according to PI-RAD 3 scores was potentially useful, and the grayscale range (42.6-91.8) was a potential predictor for csPC diagnosis.”

For more information on this research see: Usefulness of grayscale values of hypoechoic lesions matched with target lesions observed on magnetic resonance imaging for the prediction of clinically significant prostate cancer. BMC Urology, 2022,22(1):1-8. (BMC Urology - http://bmcurol.biomedcentral.com). The publisher for BMC Urology is BMC.

A free version of this journal article is available at https://doi.org/10.1186/s12894-022-01111-7.

Our news editors report that additional information may be obtained by contacting Dong Gyun Kim, Department of Urology, National Health Insurance Service Ilsan Hospital. Additional authors for this research include Jeong Woo Yoo, Kyo Chul Koo, Byung Ha Chung, Kwang Suk Lee.

(Our reports deliver fact-based news of research and discoveries from around the world.)